GUANGZHOU, China, July 19, 2016 /PRNewswire/ -- Chinese health products manufacturer and distributor Infinitus (China) Company Ltd., a member of LKK Health Products Group (LKKHPG), officially kicked off the Chinese Herbal Medicine Research and Safety Assessment Center (the Center) in Guangzhou on July 15. The Center is designed to take advantage of modern science to conduct research on quality standards, safety, measurement technologies, processing techniques, application theories, as well as the mechanism that controls the effectiveness of Chinese herbal medicine. In addition, the Center will provide professional support in terms of science-based technologies and safety assessment in a move to boost the orderly, scientific and healthy development of the Chinese herbal medicine industry.
Global demand for natural medicine has been rising for years, helping a variety of products with Chinese herbal medicines as active ingredients rise in popularity globally. Despite being a traditional leader in Chinese herbal medicine, China is relatively weak when it comes to safety control. Safety assessment is one of the hot topics when it comes to discussing challenges facing modern research into Chinese herbal medicine.
Mr. Tim Chun, Senior Vice President of LKKHPG said : "In-depth research into Chinese herbal medicine and product safety will not only boost safety applications, but also help Chinese players stay current with international research technologies, serving to enhance China's competitiveness in the global Chinese herbal medicine market."
The Center is committed to becoming a renowned research platform as well as an independent and professional safety assessment center for Chinese herbal medicine. With an initial investment of RMB43 million, the center comes equipped with advanced scientific measuring tools and instruments in accordance with standards of China's key national labs as well as professional physical, chemical and precision lab instruments specifically tailored for Chinese herbal medicine. In addition, the Center will join with leading domestic and foreign research institutions and teams to build a multidisciplinary and participatory research platform. To date, the Center has received support from a number of institutions and universities including the Guangdong Institute of Microbiology, the University of Macau, the Guangzhou University of Chinese Medicine, the South China University of Technology and South China Agricultural University as well as other national key laboratories.
The Joint Research Center for Safety and function of Edible Medicinal Fungi (" Fungi Center"), launched on the same day, was set up jointly by Infinitus (China) and the Guangdong Institute of Microbiology, an organization with a long list of achievements in the research of edible and medicinal fungi. The fungi Center is the Center's first platform built and shared with an external organization. The fungi Center will focus on research into the medical properties of edible and medicinal fungi and how they interact with the human body as well as how these findings can be applied to further technological development, biological risk assessment across the industry chain as well as prevention and control technologies. In the future, the Center will build additional specialized Chinese herbal research platforms with an eye to innovation and collaborative inclusiveness.
In addition, the Center plans to provide the entire industry and the larger Traditional Chinese Medicine community with technical support and safety assessment services. In the future, the Center plans to address demand from consumers for evaluation in the safety and effectiveness of Chinese herbal products by providing them with Chinese herbal-related third-party testing services.
With over two decades of experience in research into and development of Chinese herbal health products, Infinitus has invested over RMB100 million (approx. US$15 million) in product development each year. With the support of China's largest team engaged in development of Chinese herbal health products, the company has proprietary technology on Herbal Polysaccharides, Schizandrin B, Compound Whitening Factor, Bioactive Peptide and many others. Infinitus has now expanded its presence in Chinese mainland, Hong Kong, Taiwan and Malaysia.
Mr. Harry Yeung, Senior Vice President of LKKHPG, said, "the launch of the Center will support the group's new product development and product testing services, as well as boost the standardization and modernization of the Chinese herbal industry worldwide, serving to benefit more consumers."
About LKK Health Products Group ( www.lkkhpg.com )
LKK Health Products Group is a member of Lee Kum Kee Group, a century-old Hong Kong enterprise. Headquartered in Hong Kong, LKKHPG is engaged in Chinese herbal plantations, the R&D, production, sales of and services supporting Chinese herbal health products, mobile internet platforms, and property investment, with nearly 4,620 employees. Member companies of LKKHPG include Infinitus (China) Company Ltd., Infinitus (Hong Kong) Company Ltd., Infinitus International Company Ltd., Infinitus International (Malaysia) Sdn Bhd., Naturale (China) Pharma Co., Ltd., HeHa Digital Health Ltd., and Infinitus Property Investment Company Ltd.
